n.a. (TBRA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Tobira Therapeutics To Present At The 36th Annual Canaccord Genuity Growth Conference

Tobira Therapeutics To Present At The 36th Annual Canaccord Genuity Growth Conference

Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the Canaccord Genuity Growth Conference.

Tobira Therapeutics Announces Date Of 2016 Second Quarter Financial Results And CENTAUR Study Update Conference Call

Tobira Therapeutics Announces Date Of 2016 Second Quarter Financial Results And CENTAUR Study Update Conference Call

-Guest Speaker Arun Sanyal, M.D. to Speak on CENTAUR Study and NASH Landscape-

Tobira Therapeutics Announces Clinically And Statistically Significant Improvement In Liver Fibrosis From Phase 2b CENTAUR NASH Trial At One Year

Tobira Therapeutics Announces Clinically And Statistically Significant Improvement In Liver Fibrosis From Phase 2b CENTAUR NASH Trial At One Year

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced...

Tobira Therapeutics To Host Conference Call At 8:30 A.m. Eastern Time Tomorrow To Discuss CENTAUR Phase 2b Trial Results

Tobira Therapeutics To Host Conference Call At 8:30 A.m. Eastern Time Tomorrow To Discuss CENTAUR Phase 2b Trial Results

Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that it will hold a teleconference and webcast at 8:30 a.

Tobira's Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH

Tobira's Cenicriviroc Reduces Inflammation And Fibrosis In Animal Models Of Chronic Liver And Kidney Disease Including NASH

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced that data from...

Tobira's Cenicriviroc Shown To Reduce Liver Injury In Independent Research Published In The Journal Hepatology

Tobira's Cenicriviroc Shown To Reduce Liver Injury In Independent Research Published In The Journal Hepatology

Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced that data from a...

5 Stocks Under $10 Set to Soar Higher

5 Stocks Under $10 Set to Soar Higher

These five stocks trading for less than $10 a share are within range of triggering breakout trades.

Tobira Therapeutics Becomes Oversold (TBRA)

Tobira Therapeutics Becomes Oversold (TBRA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.